Blue-chip name Amgen, Inc.  (NASDAQ:AMGN) earlier reported its olpasiran therapy helped reduce cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD), according to topline data from its phase 2 trial.
### Instruction: What is the sentiment of this news? Please choose an answer from {negative/neutral/positive}
### Input: Blue-chip name Amgen, Inc.  (NASDAQ:AMGN) earlier reported its olpasiran therapy helped reduce cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD), according to topline data from its phase 2 trial.
### Response: moderately positive